Share on StockTwits
 

Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reaffirmed by investment analysts at Cenkos Securities Ltd in a note issued to investors on Monday, AR Network reports.

Shire PLC (NASDAQ:SHPG) traded up 1.33% during mid-day trading on Monday, hitting $165.12. The stock had a trading volume of 594,078 shares. Shire PLC has a 52 week low of $86.01 and a 52 week high of $162.98. The stock’s 50-day moving average is $147.8 and its 200-day moving average is $129.9.

Shire PLC (NASDAQ:SHPG) last issued its quarterly earnings data on Thursday, February 13th. The company reported $2.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.02 by $0.24. The company had revenue of $1.33 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter in the previous year, the company posted $0.22 earnings per share. The company’s revenue for the quarter was up 12.2% on a year-over-year basis. On average, analysts predict that Shire PLC will post $9.41 earnings per share for the current fiscal year.

A number of other analysts have also recently weighed in on SHPG. Analysts at Deutsche Bank reiterated a “buy” rating on shares of Shire PLC in a research note on Friday. Separately, analysts at RBC Capital raised their price target on shares of Shire PLC from $153.00 to $170.00 in a research note on Friday. They now have a “sector perform” rating on the stock. Finally, analysts at Leerink Swann set a $170.00 price target on shares of Shire PLC in a research note on Wednesday, February 5th. Six research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $155.40.

Shire plc (NASDAQ:SHPG) is a specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.